NFE2L2 and neoplasm: However, in several malignancies, persistent or aberrant activation of Nrf2—often due to mutations in its negative regulator KEAP1—can contribute to tumor cell survival, proliferation, and resistance to chemotherapy and radiotherapy [57,58].